Patents by Inventor Kam Leong
Kam Leong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10245319Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: GrantFiled: September 7, 2017Date of Patent: April 2, 2019Assignee: Duke UniversityInventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Publication number: 20180099044Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: ApplicationFiled: September 7, 2017Publication date: April 12, 2018Inventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Patent number: 9901553Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.Type: GrantFiled: May 13, 2016Date of Patent: February 27, 2018Assignee: Duke UniversityInventors: Bruce A. Sullenger, Sabah Oney, Tung Suet Ruby Lam, Kam Leong
-
Patent number: 9782475Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: GrantFiled: July 21, 2014Date of Patent: October 10, 2017Assignee: Duke UniversityInventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Patent number: 9567649Abstract: Methods for the identification of microorganisms or infectious disorders are disclosed, comprising obtaining a suitable sample from sources such as persons, animals, plants, food, water or soil. The methods also comprise providing tailored nucleic acid substrate(s) designed to react with a type 1 topoisomerase from one or more microorganism(s) or infectious agent(s), and incubating said substrate with said sample, or extracts or preparations from the sample, so that the substrate is processed by said topoisomerase if said microorganism(s) or infectious agent(s) is present in the sample. Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are also provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme.Type: GrantFiled: October 26, 2013Date of Patent: February 14, 2017Inventors: Jørn Erland Koch, Magnus Stougaard, Birgitta Ruth Knudsen, Sissel Juul, Kam Leong, Yi-Ping Ho, Felicie F. Andersen
-
Publication number: 20160250165Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.Type: ApplicationFiled: May 13, 2016Publication date: September 1, 2016Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Sabah Oney, Tung Suet Ruby Lam, Kam Leong
-
Patent number: 9340591Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.Type: GrantFiled: September 30, 2009Date of Patent: May 17, 2016Assignee: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Sabah Oney, Tung Suet Ruby Lam, Kam Leong
-
Publication number: 20150023909Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Inventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Publication number: 20150018228Abstract: Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme.Type: ApplicationFiled: August 31, 2012Publication date: January 15, 2015Inventors: Jørn Erland Koch, Magnus Stougaard, Birgitta Ruth Knudsen, Sissel Juul, Kam Leong, Megan Yi-Ping Ho, Felicie F. Andersen
-
Patent number: 8802076Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: GrantFiled: October 4, 2011Date of Patent: August 12, 2014Assignee: Duke UniversityInventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Publication number: 20140155284Abstract: Methods for the identification of microorganisms or infectious disorders are disclosed, comprising obtaining a suitable sample from sources such as persons, animals, plants, food, water or soil. The methods also comprise providing tailored nucleic acid substrate(s) designed to react with a type 1 topoisomerase from one or more microorganism(s) or infectious agent(s), and incubating said substrate with said sample, or extracts or preparations from the sample, so that the substrate is processed by said topoisomerase if said microorganism(s) or infectious agent(s) is present in the sample. Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are also provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme.Type: ApplicationFiled: October 26, 2013Publication date: June 5, 2014Inventors: Jørn Erland Koch, Magnus Stougaard, Birgitta Ruth Knudsen, Sissel Juul, Kam Leong, Yi-Ping Ho, Felicie F. Andersen
-
Publication number: 20120107268Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.Type: ApplicationFiled: October 4, 2011Publication date: May 3, 2012Inventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
-
Patent number: 8003125Abstract: A cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug. The polymer is selected from poly(ethylene glycol), derivatives thereon or a copolymer with a poly(ethylene glycol) segment. The copolymer with a poly(ethylene glycol) segment may include a polymer selected from the group consisting of polyesters, polyurethanes, polyamides, polyethers, polysaccharides, poly(amino acid)s, polypeptides, and proteins. The composition may be injected subcutaneously, intramuscularly, intradermally, or intracranially.Type: GrantFiled: May 18, 2001Date of Patent: August 23, 2011Assignee: Agency for Science, Technology and ResearchInventors: Jun Li, Hanry Yu, Kam Leong
-
Publication number: 20100184822Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.Type: ApplicationFiled: September 30, 2009Publication date: July 22, 2010Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Sabah Oney, Tung Suet Ruby Lam, Kam Leong
-
Publication number: 20080057128Abstract: A drug delivery system that includes micelles formed from an amphiphilic copolymer that includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), and a therapeutically effective amount of at least one therapeutic agent intimately contained within the micelles. In one preferred embodiment of the invention, the A polymer block is poly(ethylene oxide) (PEO) and the B polymer block is poly[(R)-3-hydroxybutyrate] (PHB), and the copolymer is the triblock ABA copolymer PEO-PHB-PEO. A method of synthesizing the amphiphilic triblock copolymer is also provided.Type: ApplicationFiled: October 29, 2007Publication date: March 6, 2008Inventors: Jun Li, Xu Li, Xiping Ni, Kam Leong
-
Publication number: 20070259032Abstract: A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue.Type: ApplicationFiled: May 1, 2007Publication date: November 8, 2007Inventors: Corinne Bright, Rachel Bright, Eric Churchill, Kam Leong, Daria Rosen
-
Patent number: 7247310Abstract: A tumor vaccine which comprises a microparticle or a lysate prepared from a solidified tumor material selected from the group consisting of a tumor tissue, a tumor cell, and a component thereof, and at least one cytokine and/or cytokine-inducing agent (e.g., a granulocyte-macrophage-colony stimulating factor and/or interleukin-2 and the like), and optionally an adjuvant. The vaccine can be easily prepared and widely applied for prevention of recurrence, inhibition of metastasis and therapeutic treatment regardless of a type of a tumor, and has excellent antitumor effect.Type: GrantFiled: February 9, 2000Date of Patent: July 24, 2007Assignees: Cell-Medicine, Inc., RikenInventors: Tadao Ohno, Bao Gang Peng, Kam Leong, Shu Qin Liu
-
Publication number: 20070020244Abstract: Described herein are fiber compositions, methods of generating the fiber compositions, and methods of using the fiber compositions in various applications utilizing fiber constructs, including for example, tissue engineering.Type: ApplicationFiled: March 30, 2006Publication date: January 25, 2007Applicant: The Johns Hopkins UniversityInventors: Andrew Aun Wan, Kam Leong
-
Publication number: 20070009951Abstract: An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-? production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.Type: ApplicationFiled: September 5, 2006Publication date: January 11, 2007Inventors: Shyam Mohapatra, Mukesh Kumar, Shau-Ku Huang, Kam Leong, Aruna Behera, Li-Chen Chen, Cristina de la Cruz
-
Patent number: 7118888Abstract: An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-? production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.Type: GrantFiled: February 12, 2002Date of Patent: October 10, 2006Assignees: University of South Florida Board of Trustees, Johns Hopkins UniversityInventors: Shyam S. Mohapatra, Mukesh Kumar, Shua-ku Huang, Kam Leong